Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

TNT003

 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Monoclonal Antibodies

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Targeted Therapies for Autoimmune Bullous Diseases: Current Status
Autoimmune bullous skin disorders are rare but meaningful chronic inflammatory diseases, many of which had a poor or devastating… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
2017
2017
Complement-Mediated Enhancement of Monocyte Adhesion to Endothelial Cells by HLA Antibodies, and Blockade by a Specific Inhibitor of the Classical Complement Cascade, TNT003
Background Antibody-mediated rejection (AMR) of most solid organs is characterized by evidence of complement activation and/or… Expand
2017
2017
Effect of the Anti‐C1s Humanized Antibody TNT009 and Its Parental Mouse Variant TNT003 on HLA Antibody–Induced Complement Activation—A Preclinical In Vitro Study
The classic pathway (CP) of complement is believed to significantly contribute to alloantibody‐mediated transplant injury, and… Expand
2016
2016
Uncoupling complement C1s activation from C1q binding in apoptotic cell phagocytosis and immunosuppressive capacity.
Complement activation contributes to inflammation in many diseases, yet it also supports physiologic apoptotic cells (AC… Expand
2015
2015
An Anti-C1s Monoclonal, TNT003, Inhibits Complement Activation Induced by Antibodies Against HLA
Antibody‐mediated rejection (AMR) of solid organ transplants (SOT) is characterized by damage triggered by donor‐specific… Expand
Highly Cited
2014
Highly Cited
2014
TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins.
Activation of the classical pathway (CP) of complement is often associated with autoimmune disorders in which disease pathology… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2014
2014
Classical Pathway of Complement Activation in ITP: Inhibition By TNT003, a Novel C1s Inhibitor
Background: Immune thrombocytopenic purpura (ITP) is an autoimmune disorder in which antiplatelet antibodies mediate accelerated… Expand
2014
2014
TNT003, a Novel Anti-C1s Monoclonal Antibody, Inhibits Anti-HLA Antibody Induced Complement Deposition.: Abstract# A215
 
2013
2013
TNT009, a Classical Complement Pathway Specific Inhibitor, Prevents Complement Dependent Hemolysis Induced By Cold Agglutinin Disease Patient Autoantibodies
Cold agglutinin disease (CAD) is an autoimmune hemolytic anemia in which autoantibodies bind to red blood cells (RBC) at… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE